Evidence map›Paper›PMID 27565576›Full record

ArticleImmunology2016

Functional exhaustion of CD4

Didem Ozkazanc, Digdem Yoyen-Ermis, Ece Tavukcuoglu, Yahya Buyukasik, Gunes Esendagli

Open access · bronzeAbstract read
In one paragraph

Article in Immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 69 citations in OpenAlex.

  1. Article
  2. TIM-3 in AML: pathogenic roles and therapeutic targetability.Clinical and experimental medicine · 2026
    Review
  3. Article
  4. CD4Cancer biology & medicine · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Frontiers in immunology · 2024
    Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Journal of oncology · 2023
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Didem OzkazancDepartment of Basic Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Digdem Yoyen-ErmisDepartment of Basic Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Ece TavukcuogluDepartment of Basic Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Yahya BuyukasikDepartment of Haematology, Hacettepe University Medical Faculty, Ankara, Turkey.
Gunes EsendagliDepartment of Basic Oncology, Hacettepe University Cancer Institute, Ankara, Turkey. gunes.esendagli@lycos.com.
Hacettepe University Hospital · TRHacettepe University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To cope with immune responses, tumour cells implement elaborate strategies such as adaptive resistance and induction of T-cell exhaustion. T-cell exhaustion has been identified as a state of hyporesponsiveness that arises under continuous antigenic stimulus. Nevertheless, contribution of co-stimulatory molecules to T-cell exhaustion in cancer remains to be better defined. This study explores the role of myeloid leukaemia-derived co-stimulatory signals on CD4

Indexed as

AdultAgedAntigens, CDCD4-Positive T-LymphocytesCell Line, TumorCoculture TechniquesCytokinesFemaleHepatitis A Virus Cellular Receptor 2HumansImmunosenescenceLeukemia, MyeloidLymphocyte Activation Gene 3 ProteinMaleMiddle AgedProgrammed Cell Death 1 ReceptorAntigens, CDCytokinesHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2Lag3 protein, humanLymphocyte Activation Gene 3 ProteinPDCD1 protein, humanProgrammed Cell Death 1 Receptorcancerhelper T cellimmune escapeinterleukin-2lymphocyte activation gene 3programmed cell death 1T-cell immunoglobulin and mucin domain-containing protein-3

Identifiers

PMID27565576
PMCPMC5095494
OpenAlexW2510286120

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.